Patents Represented by Attorney Lawrence W. Flynn
  • Patent number: 4479938
    Abstract: Patients having a clotting factor defect can be successfully treated by the administration of a composition containing effective hemostatic amounts of factor VIIa. Preferably, the factor VIIa is substantially free of factors IXa and Xa. Procedures for preparing the above therapeutic compositions are also described.
    Type: Grant
    Filed: June 14, 1982
    Date of Patent: October 30, 1984
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventor: William R. Thomas
  • Patent number: 4480029
    Abstract: Biological indicators are used to evaluate the effectiveness of virus inactivation conducted on virus-contaminated, protein-containing compositions. The indicators comprise dry protein and a predetermined titer of infectious virus.
    Type: Grant
    Filed: April 27, 1981
    Date of Patent: October 30, 1984
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventor: Gary H. Dolana
  • Patent number: 4413741
    Abstract: An improved hanger assembly is provided for use with bottles containing liquids, particularly glass vessels for holding liquids to be administered parenterally. The hanger includes a frangibly-activated hinge that biases the rotation of a hook or loop into a position to enable safe and expeditious hanging of the bottle. The assembly is a substantially rigid unitary construction made of material having a substantially uniform thickness, i.e., not having any elements protruding outside of the general profile of the bottle to be hung. The assembly maintains this profile until the frangibly-activated hinge is broken to allow rotation of the hook or loop into a position to permit hanging. Further, use of a frangibly-activated hinge permits the use of design and materials for the hanger assembly which reduce the risks of tearing the hanger and improve the bottle orientation when it is hung.
    Type: Grant
    Filed: December 16, 1981
    Date of Patent: November 8, 1983
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventor: Leon T. Curchack
  • Patent number: 4411795
    Abstract: Lipin particles are removed from aqueous suspension by adsorption on hydrophilic macromolecules substituted with pendant hydrophobic groups. Particularly beneficial results are achieved by use of pendant hydrophobes linked by strongly ionogenic groups to water insoluble carriers.
    Type: Grant
    Filed: February 26, 1981
    Date of Patent: October 25, 1983
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventor: Wayne P. Olson
  • Patent number: 4397779
    Abstract: Compounds useful as tracers in the radioimmunoassay of xanthine derivatives such as theophylline and pharmacologically related drugs: ##STR1## wherein at least one R.sub.1, R.sub.3, R.sub.7 or R.sub.8 is a radioiodinated radical and wherein, if not substituted by a radioiodinated radical, the remaining R.sub.1, R.sub.3, R.sub.7 or R.sub.8 groups are otherwise identical to the substituents at these positions in the xanthine derivative to be assayed. Ordinarily, R.sub.1 is hydrogen, acetate or methyl; R.sub.3 is methyl; R.sub.7 is hydrogen, acetate or methyl; and R.sub.8 is hydrogen. The tracers are made by linking radioiodinatable or preradioiodinated radicals to the xanthine derivative which is to be assayed. The tracers may be employed in known radioimmunoassay techniques.
    Type: Grant
    Filed: May 28, 1981
    Date of Patent: August 9, 1983
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventors: Ernest V. Groman, Michael D. Cabelli
  • Patent number: 4376819
    Abstract: A p-nitrophenyl hydrolase contaminant present in Limulus coagulase sources interferes in, i.e., inhibits, coagulase-based assays for endotoxin. The contaminant inhibitor enzyme may be removed from coagulase by physical separation or by selective denaturation, for example by adjusting the pH of a coagulase solution to about from 8.5 to 11. Inhibitor-free coagulase is a novel composition. The coagulase activity of the composition is adjusted to a predetermined level to provide a standardized coagulase reagent for use in endotoxin assays.
    Type: Grant
    Filed: February 23, 1981
    Date of Patent: March 15, 1983
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventors: R. Clark Brown, Richard Cotter, Susan K. Young
  • Patent number: 4357310
    Abstract: Nonspecific binding of radioiodinated protein hormones in specific-receptor binding assays is reduced by including a nonionic detergent with the tracer during storage prior to the assay.
    Type: Grant
    Filed: August 8, 1980
    Date of Patent: November 2, 1982
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventors: Catherine T. Chan, Debra A. Gravallese
  • Patent number: 4357343
    Abstract: A novel amino acid composition is provided for the nutritional maintenance of renal failure patients.
    Type: Grant
    Filed: June 26, 1981
    Date of Patent: November 2, 1982
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventors: David C. Madsen, Hugh N. Tucker
  • Patent number: 4357321
    Abstract: A composition comprising about from 37 to 190 units of factor VII/ml and about from 25 to 80 units of factor VIIa/ml is administered to patients in the treatment of clotting factor inhibitors. The composition may include activated and unactivated clotting factors such as factors IX, IXa, Xa and X.
    Type: Grant
    Filed: May 11, 1981
    Date of Patent: November 2, 1982
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventor: William R. Thomas
  • Patent number: 4336157
    Abstract: The green shade imparted to serum or plasma by biliverdin is eliminated by contacting the contaminated fluid with dithionite ion.
    Type: Grant
    Filed: June 27, 1980
    Date of Patent: June 22, 1982
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventor: Nicholas J. Kartinos
  • Patent number: 4332786
    Abstract: The binding of vitamin B-12 by natural substances in samples assayed for vitamin B-12 is reduced by heating the test sample in an alkaline buffer comprising thioglycerol and denaturing agent having the formula (R).sub.2 NC(A)N(R).sub.2, wherein R is hydrogen or lower alkyl and A is oxygen or hydroxyl.
    Type: Grant
    Filed: May 15, 1980
    Date of Patent: June 1, 1982
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventors: Michael D. Cabelli, Ernest V. Groman
  • Patent number: 4323478
    Abstract: An improved method and apparatus is disclosed for producing frozen particulate compositions from liquid feedstock. A continuous stream of liquid feedstock is passed through an orifice and into a liquid freezant without the orifice contacting the freezant. Compositions produced by this improved method have low proportions of fine and large particles, yielding particularly beneficial results in the case of quality control materials. The compositions are advantageously employed in automated weighing and filling apparatus.
    Type: Grant
    Filed: December 19, 1979
    Date of Patent: April 6, 1982
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventors: Thomas H. Adams, James P. Beck, Robert C. Menson
  • Patent number: 4297494
    Abstract: Compounds useful as tracers in the radioimmunoassay of xanthine derivatives such as theophylline and pharmacologically related drugs: ##STR1## Wherein at least one R.sub.1, R.sub.3, R.sub.7 or R.sub.8 is a radioiodinated radical and wherein, if not substituted by a radioiodinated radical, the remaining R.sub.1, R.sub.3, R.sub.7 or R.sub.8 groups are otherwise identical to the substituents at these positions in the xanthine derivative to be assayed. Ordinarily, R.sub.1 is hydrogen, acetate or methyl; R.sub.3 is methyl; R.sub.7 is hydrogen, acetate or methyl; and R.sub.8 is hydrogen. The tracers are made by linking radioiodinatable or preradioiodinated radicals to the xanthine derivative which is to be assayed. The tracers may be employed in known radioimmunoassay techniques.
    Type: Grant
    Filed: August 9, 1978
    Date of Patent: October 27, 1981
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventors: Ernest V. Groman, Michael D. Cabelli
  • Patent number: 4292296
    Abstract: Free analytes in samples containing free analytes and receptorbound analytes are determined by absorbing at least a portion of free analyte from the sample with insolubilized receptor or receptor which is then made insoluble, washing the insoluble receptor, adding labelled sample analyte or labelled sample analyte receptor, incubating, washing the insoluble phase free of the soluble phase and determining the label in either phase. The method solves a long standing need in the assay of free thyroid hormones.
    Type: Grant
    Filed: September 12, 1978
    Date of Patent: September 29, 1981
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventor: George H. Parsons, Jr.
  • Patent number: 4292405
    Abstract: A system is provided for testing the sterility of a plurality of samples. The samples are fed by gravity to and through a first conduit which branches into a pair of conduits terminating in two separate test chambers. Each of the test chambers has a main chamber portion and a filter therein. The sample material is gravity fed into the main chamber portions and a vacuum pump is used to draw the liquid material through the filter and out of the test chamber. Test media is introduced to each of the test chambers through an injection site and the test chambers are incubated.
    Type: Grant
    Filed: February 19, 1980
    Date of Patent: September 29, 1981
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventors: Carmine C. Mascoli, J. Lee Pope, Jr., Phillip L. Weber
  • Patent number: 4288538
    Abstract: Test methods in which an enzyme conversion of at least one member of a family of compounds to an analyte precedes an immunoassay of the analyte are improved by conducting the enzyme conversion step substantially simultaneous with the immunoassay. A novel composition is provided for conducting the improved test method.
    Type: Grant
    Filed: January 31, 1979
    Date of Patent: September 8, 1981
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventors: Ernest V. Groman, Marian E. Sacco
  • Patent number: 4271140
    Abstract: The performance of double receptor, specific binding assays is improved by use of a receptor complex having the structureA.sub.BL (BL).sub.n A.sub.1wherein BL is a binding ligand, A.sub.BL is a receptor specific for binding ligand, A.sub.1 is a receptor, BL is covalently bonded to A.sub.1 and A.sub.BL is reversibly bonded to BL. Generally A.sub.BL is absorbed onto an insoluble surface and A.sub.1 is an antibody to the substance being assayed. The complex has particular utility in coated tube and rechargeable radioimmunoassay systems.
    Type: Grant
    Filed: August 1, 1978
    Date of Patent: June 2, 1981
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventor: James R. Bunting
  • Patent number: 4267272
    Abstract: Prostatic acid phosphatase is immunologically unstable under typical laboratory conditions. Thus it is necessary to combine a stabilizing composition with samples taken for immunological assay of prostatic acid phosphatase content, and to similarly stabilize prostatic acid phosphatase-containing reagents in kits used to assay the enzyme.
    Type: Grant
    Filed: November 5, 1979
    Date of Patent: May 12, 1981
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventor: Lee Josephson
  • Patent number: 4250162
    Abstract: Samples are extracted with organic solvents and the organic solvents are then placed directly into antiserum coated test tubes and dried. The improved method combines steps heretofore performed separately, resulting in improved assay convenience, cost and accuracy.
    Type: Grant
    Filed: July 2, 1979
    Date of Patent: February 10, 1981
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventor: Ernest V. Groman
  • Patent number: 4250334
    Abstract: A method of synthesizing fluoromethylhexafluoroisopropyl ether comprises adding hexafluoroisopropyl alcohol to a mixture comprising a stoichiometric excess of paraformaldehyde and hydrogen fluoride, plus sufficient sulfuric acid to sequester most of the water produced by the reaction. The mixture is maintained at a temperature of at least 57.degree. C., to cause vapor formation by boiling of the fluoromethylhexafluoroisopropyl ether formed. The vapor is then collected and condensed, and may be purified by distillation.
    Type: Grant
    Filed: December 26, 1979
    Date of Patent: February 10, 1981
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventors: Clifford L. Coon, Robert L. Simon